Meeting
2017 ASCO Annual Meeting
A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
Authors
Andrea B. Apolo
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Andrea B. Apolo , Amir Mortazavi , Mark N. Stein , Nicole N. Davarpanah , Rosa Maria Nadal , Howard L. Parnes , Yangmin M. Ning , Deneise C Francis , Lisa M Cordes , Marilise Anne Berniger , Seth M. Steinberg , Piyush K. Agarwal , Mohammadhadi H. Bagheri , Swati Nanda , Paul Monk III, Tiffany Lancaster , Tina Moore , Rene Costello , Donald P. Bottaro , Sumanta K. Pal
Organizations
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, National Cancer Center, National Institutes of Health, Bethesda, MD, Division of Cancer Prevention, National Cancer Institute at the National Institutes of Health, Bethesda, MD, FDA, Silver Spring, MD, National Institutes of Health, Bethesda, MD, Leidos Biomedical Inc., National Cancer Institute, Bethesda, MD, Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD, National Cancer Institute at the National Institutes of Health, Bethesda, MD, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, The Ohio State University, Columbus, OH, City of Hope, Duarte, CA, Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD, City of Hope Comprehensive Cancer Center, Duarte, CA
Research Funding
NIH
Background: We report the safety and clinical activity of the combination of CaboNivo and CaboNivoIpi in pts with mUC and other mGU tumors (NCT02496208). Methods: In this phase I trial 30 pts were treated in 4 dose levels (DL) for part 1 (CaboNivo) and 18 pts were treated in 3 DL for part 2 (CaboNivoIpi). Pts received Cabo PO daily and Nivo IV (part 1) with Ipi 1mg/kg x 4 doses q3wks (part 2). A mUC and a renal cell carcinoma (RCC) expansion cohort of CaboNivo has initiated enrollment. Tumors were assessed for overall response rate (ORR) q8wks (RECIST 1.1). Adverse events (AEs) were graded (G) by NCI-CTCAE v4.0. Results: From 7/22/15 to 12/31/2016, 48pts (CaboNivo N = 30; CaboNivoIpi N = 18) (mUC N = 19; bladder urachal N = 4; bladder squamous cell carcinoma (bSCC) N = 2; germ cell tumor (GCT) N = 4; castrate-resistant prostate cancer (CRPC) N = 9; RCC N = 2, sarcomatoid RCC N = 2, Sertoli cell N = 1, and trophoblastic tumor N = 1 were treated. Median age was 58 (range 35-77), 41 (85%) were male. Common treatment-related G1/2 AEs for CaboNivo: ALT increase (67%), fatigue (63%), diarrhea (60%), hypothyroidism (57%); CaboNivoIpi: fatigue (72%), diarrhea (61%), anorexia (61%); Grade 3 AEs for CaboNivo: hypertension (23%), neutropenia (17%), hypophosphatemia (13%), lipase increase (10%), fatigue (7%), aseptic meningitis (3%); CaboNivoIpi: hypophosphatemia (19%), hypertension (19%), fatigue (13%), hyponatremia (13%), nausea (13%), lipase increase (11%), colitis (6%); G4 CaboNivo: lipase increase (7%) thrombocytopenia (3%); CaboNivoIpi lipase increase (6%) There were no G5 toxicities, no DLTs. 43 pts were evaluable for response: ORR was 30% 13/43 [3 CR (2 mUC, 1 bSCC); 10 PRs (4 mUC, 2 penile, 1 sarcomatoid RCC, 1 urachal, 1 CRPC, 1 bSCC)]. ORR for CaboNivo 39% (mUC 44%); CaboNivoIpi 18% (mUC 29%). 11/13 (85%) of responses were ongoing at cutoff. Conclusions: CaboNivo and CaboNivoIpi combinations were well tolerated with no DLTs and have durable efficacy in mGU tumors particularly mUC. Rare tumors such as bSCC, urachal, and penile cancers demonstrated response to the combination. Larger cohorts of mUC and rare GU tumors are ongoing. Clinical trial information: NCT02496208
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02496208
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4562)
DOI
10.1200/JCO.2017.35.15_suppl.4562
Abstract #
4562
Poster Bd #
240
Abstract Disclosures
Similar Abstracts
Abstract
2021 Genitourinary Cancers Symposium
Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.
First Author: Andrea B. Apolo
Abstract
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
First Author: Bradley Alexander McGregor
Abstract
2023 ASCO Annual Meeting
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.
First Author: Naomi B. Haas
Abstract
2023 ASCO Annual Meeting
High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.
First Author: Julie Williamson